SAN DIEGO, Aug. 13 /PRNewswire-FirstCall/ -- Lpath, Inc. , the category leader in therapeutic agents against bioactive lipids, announced that it is now trading on the Frankfurt Stock Exchange. Lpath's trading symbol on the Frankfurt Exchange is HQ8.FSE and its WKN (German Security Code) is A0MLTX.
"Listing on the Frankfurt Exchange allows current and prospective European shareholders of Lpath, Inc. to trade our shares within European time zones and in local currency. This will broaden our corporate profile with private and institutional investors both in Germany and across Europe," said Scott Pancoast, CEO. "This listing reflects our strategy to add value by increasing accessibility and liquidity of Lpath shares for our various constituencies."
Shares traded on the Frankfurt Stock Exchange do not have an effect on Lpath total shares outstanding.
About Lpath:
Lpath, Inc., headquartered in San Diego, California, is the category leader in lipidomics-based therapeutics, an emerging field of medical science whereby bioactive signaling lipids are targeted for treating important human diseases. ASONEP(TM) (the systemic formulation of humanized form of Sphingomab(TM)) is an antibody against S1P that holds promise for the treatment of cancer and other diseases. A second product candidate, iSONEP(TM) (the ocular formulation of humanized Sphingomab), has demonstrated superior results in various preclinical AMD models. Lpath's third product candidate, Lpathomab(TM), is an antibody against LPA, a key bioactive lipid that has been long recognized as a valid disease target. The company's unique ability to generate novel antibodies against bioactive lipids is based on its ImmuneY2(TM) drug-discovery engine, which the company is using to add to its pipeline. For more information, visit www.Lpath.com
Forward-Looking Statements:
Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that required clinical trials will be successful, necessary regulatory approvals will be obtained, or the proposed treatments will prove to be safe or effective. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, our limited experience in the development of therapeutic drugs, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on research grants, current and future competition, and other risks described from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.
Contact: Scott Pancoast (858) 678-0800 x104 spancoast@lpath.comwww.lpath.com Investor Relations Liolios Group, Inc. Scott Liolios or Ron Both (949) 574-3860
Lpath, Inc.CONTACT: Scott Pancoast of Lpath, Inc., +1-858-678-0800 x104,spancoast@lpath.com; or Investor Relations, Scott Liolios or Ron Both, bothof Liolios Group, Inc., +1-949-574-3860, for Lpath, Inc.
Web site: http://www.lpath.com//
